Company is arranging $12 million debtor-in-possession financing from its senior secured lenders and access to its cash collateral on a consensual basis Canadian entities to pursue sale process outside of Chapter 11 BUENA, N.J. , Oct. 14, 2021 /PRNewswire/ --  Teligent, Inc.

– Update on FDA Inspection of Buena Facility – Assessing New Growth Opportunities in Injectables – Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time  – Dial in:  (877) 407-0792 US Toll Free Number     (201) 689-8263 International Number     Confirmation Number: 13721972

BUENA, N.J. , Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent , Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30,

Scheduled to Reconvene on July 21, 2021 Company Urgently Encourages Stockholders to Vote BUENA, N.J. , June 30, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey -based specialty generic pharmaceutical company (the “Company”), announced today that its Annual Meeting of

Scheduled to Reconvene on June 30, 2021 Company Urgently Encourages Stockholders to Vote BUENA, N.J. , June 18, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey -based specialty generic pharmaceutical company (the “Company”), announced today that its Annual Meeting of

– Continued Remediation Progress Being Made – Reiterating Prior Guidance of Informing FDA on Inspection Readiness During 3Q2021 – Conference Call to Be Held on May 25, 2021 at 4:30 pm Eastern Standard Time  – Dial in:  (800) 708-4540 US Toll Free Number     (847) 619-6397 US Number     Confirmation

BUENA, N.J. , May 21, 2021 (GLOBE NEWSWIRE) -- Teligent , Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Tuesday, May 25th, 2021 to discuss the first quarter ended March 31,

– Significantly strengthened balance sheet and cash position – Continued FDA Warning Letter remediation efforts – Anticipate informing FDA on inspection readiness during 3Q2021 – Conference Call to be held on May 4, 2021 at 4:30 pm Eastern Standard Time  – Dial in:  (800) 708-4540 US Toll Free

BUENA, N.J. , April 15, 2021 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey -based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective

Experienced Board Member and Investment Executive Joins Teligent, Effective Immediately BUENA, N.J. , Feb. 23, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), (" Teligent " or the "Company"), a New Jersey -based specialty generic pharmaceutical company, today announced it has appointed Carter